Tag:
rheumatoid arthritis
Latest Headlines
Latest Headlines
Cheaper generic combo found as effective in RA as blockbuster Enbrel
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
Humira carries AbbVie in its first quarter as standalone company
AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.
Pfizer appealing CHMP ruling on RA treatment Xeljanz
Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.
Cipla steamrolls into Enbrel market with biosimilar of Amgen drug
While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid arthritis blockbuster Enbrel, which it will sell in the subcontinent at a 30% discount.
Senator questions Pfizer's $2,000-a-month price on Xeljanz
Should taxpayers enjoy lower drug prices if federal money backed development? At least one U.S. senator thinks so, now that Pfizer has slapped a $2,000-per-month sticker price on the new rheumatoid arthritis drug Xeljanz.
Updated: Crescendo rolls out iPhone app for RA Dx
Crescendo Bioscience unveiled an iPhone app as a new resource for patients using its rheumatoid arthritis molecular diagnostic test.
Ignyta, Lieden University team on RA biomarker research
Ignyta will work with Leiden University Medical Center on new biomarker research involving patients with early synovitis and rheumatoid arthritis.
Inova licenses Dutch tech for RA Dx development
San Diego's Inova Diagnostics licensed some new technology developed in The Netherlands it hopes to apply to a rheumatoid arthritis diagnostic.
Data, schmata. Doctors want to feel pharma, too
Harris Interactive has been digging into physicians' response to drug brands, therapeutic area by therapeutic area, racking up more evidence for an emotional variable in the doctor-drug trust equation.
Crescendo Bioscience deploys $28M Series D to market RA Dx biomarker test
With a $28 million Series D venture round now in place, Crescendo Bioscience is focusing on boosting commercialization of its rheumatoid arthritis blood test--a novel diagnostic that gives a precise snapshot of the disease's activity levels by measuring multiple biomarkers.
